Dynavax Technologies Corporation (NASDAQ:DVAX) — Market Cap & Net Worth
Market Cap & Net Worth: Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corporation (NASDAQ:DVAX) has a market capitalization of $1.76 Billion ($1.76 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6640 globally and #2091 in its home market, demonstrating a 0.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dynavax Technologies Corporation's stock price $15.50 by its total outstanding shares 113684064 (113.68 Million). Also see DVAX asset base for a full breakdown of the balance sheet.
Dynavax Technologies Corporation Market Cap History: 2015 to 2026
Dynavax Technologies Corporation's market capitalization history from 2015 to 2026. Data shows change from $2.75 Billion to $1.76 Billion (-4.28% CAGR). Also see Dynavax Technologies Corporation operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Dynavax Technologies Corporation is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.07% | #192 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.00% | #751 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.09% | #116 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.62 Trillion | 0.12% | #353 of 602 |
Weight: Dynavax Technologies Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dynavax Technologies Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dynavax Technologies Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Dynavax Technologies Corporation share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.24x
Dynavax Technologies Corporation's market cap is 5.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
53.16x
Dynavax Technologies Corporation's market cap is 53.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.75 Billion | $4.05 Million | -$106.79 Million | 678.17x | N/A |
| 2016 | $449.05 Million | $11.04 Million | -$112.44 Million | 40.66x | N/A |
| 2017 | $2.13 Billion | $327.00K | -$95.15 Million | 6501.20x | N/A |
| 2018 | $1.04 Billion | $8.20 Million | -$158.90 Million | 126.89x | N/A |
| 2019 | $650.27 Million | $35.22 Million | -$152.60 Million | 18.46x | N/A |
| 2020 | $505.89 Million | $46.55 Million | -$75.24 Million | 10.87x | N/A |
| 2021 | $1.60 Billion | $439.44 Million | $76.71 Million | 3.64x | 20.85x |
| 2022 | $1.21 Billion | $722.68 Million | $293.16 Million | 1.67x | 4.13x |
| 2023 | $1.59 Billion | $232.28 Million | -$6.39 Million | 6.84x | N/A |
| 2024 | $1.45 Billion | $277.25 Million | $27.31 Million | 5.24x | 53.16x |
Competitor Companies of DVAX by Market Capitalization
Companies near Dynavax Technologies Corporation in the global market cap rankings as of September 16, 2026. Review DVAX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Dynavax Technologies Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #627 globally with a market cap of $44.32 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #639 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #662 globally with a market cap of $41.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #627 | GALDERMA GROUP AG | NYSE:GALDY | $44.32 Billion | $38.01 |
| #639 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.60 |
| #662 | Haleon plc | NYSE:HLN | $41.35 Billion | $9.39 |
Dynavax Technologies Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Dynavax Technologies Corporation's market cap moved from $2.75 Billion to $ 1.76 Billion, with a yearly change of -4.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.76 Billion | +0.78% |
| 2025 | $1.75 Billion | +20.44% |
| 2024 | $1.45 Billion | -8.66% |
| 2023 | $1.59 Billion | +31.39% |
| 2022 | $1.21 Billion | -24.38% |
| 2021 | $1.60 Billion | +216.18% |
| 2020 | $505.89 Million | -22.20% |
| 2019 | $650.27 Million | -37.49% |
| 2018 | $1.04 Billion | -51.07% |
| 2017 | $2.13 Billion | +373.42% |
| 2016 | $449.05 Million | -83.65% |
| 2015 | $2.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Dynavax Technologies Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.76 Billion USD |
| MoneyControl | $1.76 Billion USD |
| MarketWatch | $1.76 Billion USD |
| marketcap.company | $1.76 Billion USD |
| Reuters | $1.76 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also devel… Read more